GlassScriptPhysician profile
Richard B Troy
NPI 1922110212
$4,362.65
in general payments reported to CMS, 2019-2025
36 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $282 · 2021: $915 · 2022: $667 · 2023: $1,087 · 2024: $188 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $608.04 | 2019-2024 | Xtandi |
| Myovant Sciences INC. | $540.88 | 2021-2022 | |
| Janssen Biotech, INC. | $505.37 | 2019-2025 | Erleada, Akeega |
| Boston Scientific Corporation | $427.22 | 2019-2025 | Ams 700, Tria Firm |
| Sumitomo Pharma America, INC. | $302.30 | 2023-2025 | Orgovyx, Gemtesa |
| Amgen INC. | $227.10 | 2019-2023 | Xgeva |
| Travere Therapeutics, INC. | $219.93 | 2019-2021 | |
| Coloplast Corp | $197.52 | 2019-2023 | Speedicath |
| Dendreon Pharmaceuticals LLC | $155.68 | 2019-2023 | Provenge |
| Janssen Scientific Affairs, LLC | $150.00 | 2023 | Erleada |
| Abbvie INC. | $130.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $119.92 | 2021-2022 | |
| Rochester Medical Corporation | $110.79 | 2021 | |
| Antares Pharma, INC. | $54.51 | 2019-2021 | |
| Therapeuticsmd, INC. | $52.44 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $51.31 | 2019 | |
| 180 Medical, INC. | $48.71 | 2019-2023 | Gentlecath Glide |
| Tempus Ai, INC | $48.40 | 2024-2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $43.99 | 2020-2023 | Lynparza, Keytruda, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $34.23 | 2021-2022 | |
| Pfizer INC. | $31.87 | 2019-2024 | |
| Clarus Therapeutics INC. | $30.07 | 2021 | |
| Urogen Pharma, INC. | $29.64 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.13 | 2023 | |
| Endo Pharmaceuticals INC. | $28.78 | 2020-2022 | |
| Blue Earth Diagnostics | $21.84 | 2021 | |
| Teleflex LLC | $21.71 | 2023 | Urolift |
| Verity Pharmaceuticals INC. | $20.21 | 2022 | |
| Laborie Medical Technologies Corp. | $19.59 | 2024 | Goby |
| Allergan, INC. | $19.26 | 2020 | |
| Hollister Incorporated | $18.48 | 2022 | |
| Genzyme Corporation | $14.81 | 2020 | |
| Axonics, INC. | $13.74 | 2021 | |
| Avadel Specialty Pharmaceuticals, LLC | $12.08 | 2019 | |
| Neotract INC. | $11.75 | 2019 | |
| Myriad Genetic Laboratories, INC. | $11.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Troy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.